David Elkins - Bristol Myers Ex CFO

BMY Stock  MXN 1,222  16.45  1.36%   

Insider

David Elkins is Ex CFO of Bristol Myers Squibb
Age 55
Phone212 546 4000
Webhttps://www.bms.com

Bristol Myers Management Efficiency

The company has return on total asset (ROA) of 0.0613 % which means that it generated a profit of $0.0613 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1846 %, meaning that it generated $0.1846 on every $100 dollars invested by stockholders. Bristol Myers' management efficiency ratios could be used to measure how well Bristol Myers manages its routine affairs as well as how well it operates its assets and liabilities.
Bristol Myers Squibb has accumulated 39.6 B in total debt with debt to equity ratio (D/E) of 159.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Bristol Myers Squibb has a current ratio of 3.8, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Bristol Myers until it has trouble settling it off, either with new capital or with free cash flow. So, Bristol Myers' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bristol Myers Squibb sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bristol to invest in growth at high rates of return. When we think about Bristol Myers' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

CPA CFAFirst Republic Bank
N/A
Magda YrizarryVerizon Communications
N/A
Tatiana SteadCapital One Financial
N/A
Matthew FriedrichUnitedHealth Group Incorporated
53
William CarrollDelta Air Lines
65
Alain BellemareDelta Air Lines
62
Fabian BifarettiGrupo Sports World
59
Sandeep DadlaniUnitedHealth Group Incorporated
48
James DinkinsMonster Beverage Corp
56
Andrew YoungCapital One Financial
48
Robert CFAPrudential Financial
63
Gary FayardMonster Beverage Corp
67
Lee AugsburgerPrudential Financial
63
Brian ThompsonUnitedHealth Group Incorporated
N/A
Jose CelorioGrupo Sports World
39
Daniel JankiDelta Air Lines
54
Michael IoanilliFirst Republic Bank
N/A
JD IIICapital One Financial
56
William LentschDelta Air Lines
55
Emelie TirreMonster Beverage Corp
53
Susie CranstonFirst Republic Bank
N/A
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. BRISTOL MYERS operates under Drug Manufacturers - Major classification in Mexico and is traded on Mexico Stock Exchange. It employs 23300 people. Bristol Myers Squibb (BMY) is traded on Mexican Exchange in Mexico and employs 41 people.

Management Performance

Bristol Myers Squibb Leadership Team

Elected by the shareholders, the Bristol Myers' board of directors comprises two types of representatives: Bristol Myers inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bristol. The board's role is to monitor Bristol Myers' management team and ensure that shareholders' interests are well served. Bristol Myers' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bristol Myers' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jitendra Tyagi, Head India
Cari Gallman, VP Officer
David Elkins, Ex CFO
BCH BM, Ex Devel
Giovanni MD, Chairman CEO
Greg Meyers, Ex Officer
Ann Judge, Senior Vice President - Global Human Resources
Sandra Esq, Exec Counsel
Timothy Power, VP Relations
Christopher Boerner, Executive Vice President and Chief Commercial Officer

Bristol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bristol Myers a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bristol Stock Analysis

When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.